Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 101

Next Previous
Drug Profile

IMA 101

Alternative Names: ACTolog™; CD8+-T-cells-Immatics N.V.; IMA-101

Latest Information Update: 28 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immatics US
  • Developer Immatics US; University of Texas M. D. Anderson Cancer Center
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 22 Sep 2021 Immatics and the University of Texas MD Anderson Cancer Center completes phase I ACTolog trial in Solid tumours in USA (IV) in September 2021 (NCT02876510)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top